EIGR
Eiger BioPharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 1.90
- Prev close
- 1.73
- Mkt cap
- 2.55M
- Vol
- 136.27K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.73
- High
- 1.90
- Forward P/E
- -0.48
- Beta
- 1.84
- Short ratio
- 3.72
- Inst. own
- 43.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 9, 2024
- 50-d avg
- 4.59
- 200-d avg
- 10.27
- 1y target
- 30.00
Key statistics
- Market cap
- 2.55M
- Enterprise value
- 3.88M
- Trailing P/E
- 0.00
- Forward P/E
- -0.48
- PEG ratio
- 0.00
- Price / sales
- 0.17
- Price / book
- 0.00
- EPS (TTM)
- -58.50
- Beta
- 1.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 14.67M
- Revenue growth
- -20.30%
- Free cash flow
- -52.16M
- Total cash
- 44.43M
- Total debt
- 40.94M
- Return on equity
- -225.93%
- Shares outstanding
- 1.48M
- Short % of float
- 3.22%
- 50-day average
- 4.59
- 200-day average
- 10.27
Analyst view
Consensus: strong buy
- Strong buy4
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -5.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eigerbio.com
News
- Healthcare stocks fade as obesity-drug optimism fades
- Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
- Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
- Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
- Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on EIGR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APELIAN DAVID | Director | Sale | Aug 15, 2022 | 11,000 |
| CORY DAVID A | Chief Executive Officer | Stock Award(Grant) | Mar 10, 2022 | 169,183 |
| DIETZ THOMAS JOHN | Director | Purchase | Jan 22, 2023 | 0 |
| GLENN JEFFREY SCOTT | Director | Purchase | Dec 21, 2022 | 338,879 |
| KAWAS LEEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 30, 2023 | 0 |
| KAYNE RICHARD ALAN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 1, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ameriprise Financial, Inc. | 16.90% | 250,182 | 431.56K | Dec 30, 2023 |
| Propel Bio Management, LLC | 9.89% | 146,380 | 252.50K | Dec 30, 2023 |
| 683 Capital Management LLC | 4.73% | 69,999 | 120.75K | Dec 30, 2023 |
| Vanguard Group Inc | 4.10% | 60,691 | 104.69K | Dec 30, 2023 |
| Blackrock Inc. | 1.31% | 19,457 | 33.56K | Dec 30, 2023 |
| Geode Capital Management, LLC | 0.85% | 12,657 | 21.83K | Dec 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 6.08% | 89,999 | 155.25K | Dec 30, 2023 |
| Columbia Fds Ser Tr II-Columbia Seligman Technology & Information Fund | 5.22% | 77,304 | 133.35K | Nov 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.80% | 41,482 | 71.56K | Dec 30, 2023 |
| Columbia Funds Ser Tr II-Columbia Seligman Global Technology Fund | 2.39% | 35,332 | 60.95K | Jan 30, 2024 |
| Vanguard Extended Market Index Fund | 1.22% | 18,024 | 31.09K | Dec 30, 2023 |
| Fidelity Extended Market Index Fund | 0.46% | 6,756 | 11.65K | Feb 28, 2024 |